| USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 3.14M | 1.17M |
| YoY Growth | — | — | -100.0% | +167.0% | — |
| Gross Profit | — | (904,136) | (2.16M) | (10.49M) | (9.61M) |
| Gross Margin | — | — | — | -334.5% | -818.1% |
| R&D | — | 203,296 | 506,243 | 903,981 | 2.15M |
| SG&A | 4.02B | 8.42M | 11.01M | 10.93M | 10.36M |
| EBIT | — | (111.47M) | (13.61M) | (21.87M) | (22.01M) |
| EBIT Margin | — | — | — | -697.0% | -1873.1% |
| D&A | — | 904,136 | 2.16M | 2.02M | 1.79M |
| EBITDA | (2.23B) | (110.56M) | (11.45M) | (19.84M) | (20.22M) |
| EBITDA Margin | — | — | — | -632.5% | -1721.0% |
| Net Income | (18.49B) | (149.19M) | (27.56M) | (22.16M) | (22.32M) |
| Net Margin | — | — | — | -706.3% | -1900.1% |
| EPS (diluted) | $-4.77 | $-38.65 | $-7.17 | $-6.20 | $-6.40 |
| Shares (dil., M) | 4 | 4 | 4 | 4 | 3 |
Company Brief
AquaBounty Technologies, Inc., a biotechnology company, focuses on enhancing productivity in the commercial aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It offers AquAdvantage Salmon, a bioengineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Maynard, Massachusetts.
| Gross Margin | 0.0% |
| EBITDA Margin | 0.0% |
| EBIT Margin | 0.0% |
| Net Margin | 0.0% |
| FCF Margin | — |
| ROE | 4002.1% |
| ROIC | -139.8% |
| ROA | -178.8% |
| ROCE | -139.8% |
| Asset Turnover | 0.00× |
| ROIC | -139.8% |
| ROE | 4002.1% |
| ROA | -178.8% |
| ROCE | -139.8% |
| Asset Turnover | 0.00× |
| FCF Margin | — |
| Net Margin | 0.0% |
| Insider buys (12m) | — |
| Insider sells (12m) | — |
| Float | 98.5% |
| Shares Out. | 3.9M |
| Mean Target | $3.00 |
| Median Target | $3.00 |
| High Target | $4 |
| Low Target | $2 |
| vs. Mean | +246.7% |
| Buy / Hold / Sell | — |
| Cash & ST Invest. | $501.3M |
| Total Debt | $0 |
| Net Cash / (Debt) | $501.3M |
| Total Assets | $10.3B |
| Total Equity | -$1.9B |
| Goodwill & Intang. | $0 |
| Tangible Book/sh | $-488.11 |
| Current Ratio | 1.18× |
| Quick Ratio | 1.18× |
| D/E Ratio | 0.00× |
| Debt / Assets | 0.0% |
| Net Debt / EBITDA | 0.22× |
| Interest Coverage | 10.82× |
| Beta (5yr) | 1.31 |
| Revenue 1yr | +167.0% |
| Revenue 3yr | +167.0% |
| Revenue 5yr | +167.0% |
| EPS 1yr | — |
| EPS 3yr | — |
| EPS 5yr | — |
| FCF 5yr | — |
| Dividend 5yr | — |
No dividend paid.
| Capex | $0 |
| Capex / Revenue | — |
| SBC | $70.6M |
| Dividends Paid | $0 |
| Buybacks | $0 |
| Gross Margin | 0.0% |
| EBITDA Margin | 0.0% |
| EBIT Margin | 0.0% |
| Net Margin | 0.0% |
| FCF Margin | — |
| ROE | 4002.1% |
| ROIC | -139.8% |
| ROA | -178.8% |
| ROCE | -139.8% |
| Asset Turnover | 0.00× |
| ROIC | -139.8% |
| ROE | 4002.1% |
| ROA | -178.8% |
| ROCE | -139.8% |
| Asset Turnover | 0.00× |
| FCF Margin | — |
| Net Margin | 0.0% |
| Insider buys (12m) | — |
| Insider sells (12m) | — |
| Float | 98.5% |
| Shares Out. | 3.9M |
| Mean Target | $3.00 |
| Median Target | $3.00 |
| High Target | $4 |
| Low Target | $2 |
| vs. Mean | +246.7% |
| Buy / Hold / Sell | — |
| USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 3.14M | 1.17M |
| YoY Growth | — | — | -100.0% | +167.0% | — |
| Gross Profit | — | (904,136) | (2.16M) | (10.49M) | (9.61M) |
| Gross Margin | — | — | — | -334.5% | -818.1% |
| R&D | — | 203,296 | 506,243 | 903,981 | 2.15M |
| SG&A | 4.02B | 8.42M | 11.01M | 10.93M | 10.36M |
| EBIT | — | (111.47M) | (13.61M) | (21.87M) | (22.01M) |
| EBIT Margin | — | — | — | -697.0% | -1873.1% |
| D&A | — | 904,136 | 2.16M | 2.02M | 1.79M |
| EBITDA | (2.23B) | (110.56M) | (11.45M) | (19.84M) | (20.22M) |
| EBITDA Margin | — | — | — | -632.5% | -1721.0% |
| Net Income | (18.49B) | (149.19M) | (27.56M) | (22.16M) | (22.32M) |
| Net Margin | — | — | — | -706.3% | -1900.1% |
| EPS (diluted) | $-4.77 | $-38.65 | $-7.17 | $-6.20 | $-6.40 |
| Shares (dil., M) | 4 | 4 | 4 | 4 | 3 |
Company Brief
AquaBounty Technologies, Inc., a biotechnology company, focuses on enhancing productivity in the commercial aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It offers AquAdvantage Salmon, a bioengineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Maynard, Massachusetts.
| Cash & ST Invest. | $501.3M |
| Total Debt | $0 |
| Net Cash / (Debt) | $501.3M |
| Total Assets | $10.3B |
| Total Equity | -$1.9B |
| Goodwill & Intang. | $0 |
| Tangible Book/sh | $-488.11 |
| Current Ratio | 1.18× |
| Quick Ratio | 1.18× |
| D/E Ratio | 0.00× |
| Debt / Assets | 0.0% |
| Net Debt / EBITDA | 0.22× |
| Interest Coverage | 10.82× |
| Beta (5yr) | 1.31 |
| Revenue 1yr | +167.0% |
| Revenue 3yr | +167.0% |
| Revenue 5yr | +167.0% |
| EPS 1yr | — |
| EPS 3yr | — |
| EPS 5yr | — |
| FCF 5yr | — |
| Dividend 5yr | — |
No dividend paid.
| Capex | $0 |
| Capex / Revenue | — |
| SBC | $70.6M |
| Dividends Paid | $0 |
| Buybacks | $0 |